Our site uses cookies to offer a better navigation functionality, including "third party" cookies and "profiling cookies" designed to send on-line commercial communications in line with the preferences expressed by the user while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here to disable them. Upon proceeding with browsing this website, you will be consenting to the use of cookies.

Respiratory Diseases

Menarini has for years been engaged in the therapy of respiratory diseases, particularly Asthma and Chronic Obstructive Pulmonary Disease (COPD).

With this in mind the Company has focussed part of its energy on research and clinical trials with the aim of optimising existing therapeutic tools and of creating new, innovative drugs and therapeutic aids. Menarini's interest in the respiratory area is directed at scientific and cultural updating; it organises seminars and congresses with speakers of national and international fame, and divulges various types of informative material.

What is Bronchial Asthma?
Asthma is a chronic inflammatory disorder of the airways characterized by recurrent episodes of breathlessness. During an asthma exacerbation the airways thickens, the muscles of the airways contract and mucus clogs the airways, making breathing difficult. The airways become hypersensitive to environmental changes, causing wheezing and coughing. Many factors can cause an asthma exacerbation, such as viral infections, exposure to allergens (such as dust mites or pollen), smoking, air pollution. The symptoms of asthma are variable and often worsen during the night and the early morning with a severity of the disease characterized by individual variability

What is COPD?
COPD is a chronic lung disease characterized by progressive obstruction of the airways, making breathing difficult. The most important risk factor of COPD is cigarette smoking, but also the occupational exposure to irritants and environmental pollution have been recognized as a cause of the disease. COPD characteristic symptoms are chronic cough, sputum production and a progressive breathlessness, initially noted on exertion, which may strongly interfere with daily activities. In the disease progression may occur exacerbations, characterized by increased cough and sputum, wheezing, breathlessness and sometimes fever. Given the progressive nature of COPD, diagnosis and early treatment are essential to prevent complications and exacerbations, which often leads to patient hospitalization.

What Do They Have in Common?
Asthma and COPD are both chronic diseases characterized by airway obstruction. The obstruction, however, has different characteristics: asthma is often completely reversible (spontaneously or by treatment), whereas in COPD the obstruction isn’t fully reversible and usually, if exposure to noxious agents continues, gets worse gradually. Both in asthma and in COPD an airways inflammation is present, however even this aspect shows very different characteristics between the two diseases.

Menarini has committed in technological and therapeutic developement of aerosol therapy devices: by prioritizing the needs of the patient in combination with targeted therapy to the care of asthma and chronic bronchitis has developed and marketed the spacer named Fluspacer, an innovative spacer which help the patients to use aerosols medications. The constant updating of the medical profession sees Menarini engaged in major projects like the development by Menarini Foundation of conferences on issues of global importance.

Diagnostics

 

Advanced Technology

READ MORE »

Biotech

 

Menarini has been the Italian leader in the biotech industry for 30 years.

READ MORE »

Innovation and Research

 

Constant commitment to new drug research.

READ MORE »

Quality first

 
 

Quality: point of departure and arrival for our drugs.

READ MORE »